Drug Profile
Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm
Alternative Names: JAK3 inhibitors - Aclaris Therapeutics/JAKPharmLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator JAKPharm
- Developer Aclaris Therapeutics
- Class
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alopecia